At 5 years after transplantation, 87% of patients did not have tumor recurrence.
The Milan criteria (having a single tumor ≤5 cm or 2–3 tumors ≤3 cm) are used to determine which patients with hepatocellular carcinoma (HCC) can safely receive a liver transplant with low risk for tumor recurrence posttransplantation. Tumor downstaging, in which HCC is treated with locoregional therapy until it meets Milan criteria, is performed to allow more patients the option for transplantation. Success of downstaging in this setting has been reported but only from single centers.
In the current multicenter, retrospective study, researchers evaluated the probability of treatment failure (dropout from the downstaging protocol due to tumor progression, liver-related death without transplantation, or HCC recurrence post-transplantation) am…
Reviewing Author
DisclosuresNothing to disclose
DisclosuresNothing to disclose